Children with osteogenesis imperfecta are often treated with intraenous bisphosphonates. We aimed to assess thesafety and efficacy of risedronate, an orally administered third-generation bisphosphonate, in children with the disease.
Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial
ADAMI, Silvano;
2013-01-01
Abstract
Children with osteogenesis imperfecta are often treated with intraenous bisphosphonates. We aimed to assess thesafety and efficacy of risedronate, an orally administered third-generation bisphosphonate, in children with the disease.File in questo prodotto:
File | Dimensione | Formato | |
---|---|---|---|
Bishop, Lancet, 2013.pdf
non disponibili
Descrizione: articolo
Tipologia:
Documento in Post-print
Licenza:
Accesso ristretto
Dimensione
516.02 kB
Formato
Adobe PDF
|
516.02 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.